None of the analyzed disease-related factors (M-protein type, Durie–Salmon stage (DSS), International Staging System (ISS), number of prior MM therapy lines, and response of MM before ASCT) were associated with a higher CRT risk. The gene discussed is MYOM2; the disease is Miyoshi myopathy.